The phrase "achieved at baseline" is correct and usable in written English.
It can be used in contexts such as research, assessments, or evaluations where a starting point or initial measurement is referenced.
Example: "The results of the study indicated that the participants' health metrics were achieved at baseline before any interventions were applied."
Alternatives: "obtained at baseline" or "established at baseline".
Although reasonable numbers were achieved at baseline, the follow-up questionnaires were far fewer.
Adequate BP control had not been achieved at baseline in any of the enrolled patients.
A total of 922, 934 and 944 completed interviews were achieved at baseline and first and second follow-up, respectively (Table 1).
In the study reported by Palizas and coworkers [ 1], the target cardiac index was achieved at baseline in nearly 90% of patients.
Overall, a 38.4% response rate was achieved at baseline and 71.5% for the cohort (those responding at baseline and agreeing to be sent a follow-up questionnaire) at follow-up.
Differences between total scores achieved at baseline by students who completed the postintervention assessment versus students lost during the study (who did not complete the postintervention assessment) were tested with the Mann-Whitney test.
Comparisons were made between treatment responders and nonresponders according to their humoral response, which was defined as improvement achieved at ⩾3 post-baseline cycles.
Responders were (1) subjects with PRNT50 titers <10 at baseline who achieved PRNT50 titer ≥10 postvaccination or (2) those with protective titers at baseline who achieved at least a 2-fold increase in postvaccination titer.
34– 41 The mean reductions in systolic blood pressure from baseline achieved at 26 weeks were 2.59 mmHg (P=0.0008) and 2.49 mmHg (P=0.003) for liraglutide 1.2 mg and 1.8 mg, respectively, compared with 0.24 mmHg (P=0.7828) for placebo.
In subgroup analyses, at least a 15% reduction in diurnal IOP from latanoprost-treated baseline was achieved at both month 1 and month 3 by 20.3% of bimatoprost patients versus 8.2% of travoprost patients who had baseline diurnal IOPs<20 mm Hg (p = 0.053) and by 24.1% of bimatoprost patients versus 16.9% of travoprost patients who had baseline diurnal IOPs⩾20 mm Hg (p = 0.368).
A reduction in HbA1c ≥ 0.7% from baseline was achieved at 18 months in 35 and 45% of the background metformin participants on rosiglitazone and sulphonylurea, respectively [odds ratio (OR) 0.62 (95% CI 0.42, 0.90), P = 0.012] and 45 and 37% of background sulphonylurea participants using rosiglitazone and metformin [OR 1.47 (1.02.10.10), P = 0.037].
